A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Bladder Cancer: A New Era in Treatment

State of the Art in BRCA-Mutated Ovarian Cancer

Evolving Paradigms in Recurrent/Metastatic SCCHN

Back to School 2013: An Immunization Checklist

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

RISK RECOGNITION IN HEALTHCARE SETTINGS

The Immune System. The Immune System Adaptive Immune Response.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Advanced NSCLC Without Actionable Mutations

State of the Art in HCC: Immune Checkpoint Modulation

New Patient Journeys in Non-small cell lung cancer

Discussion Outline Cells of the Immune System.

The Nurse View.

Introduction to Checkpoint Inhibitors

Metastatic Renal Cell Carcinoma

Medication Nonadherence in Gout

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.

Program Goals Introduction Case 1: A 44-Year-Old Woman.

A Call to Action on Cryptogenic Stroke

Counseling Patients About Germline BRCA Mutations

The Evolving Role of Immunotherapy in NSCLC

Optimizing Management of Advanced Bladder Cancer

Checkpoint Inhibition

Basics of Immunotherapy Potential Therapeutic Targets.

The Nurse View: Top Ten Things to Know About Immune-Mediated Adverse Events.

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Managing Adverse Events With New Oral Therapies in CLL

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Immunotherapy for cSCC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Impactful Data in TD That Can Guide Treatment Decisions

Nat. Rev. Clin. Oncol. doi: /nrclinonc

In-Depth Discussion of Key Data on Immunotherapy for Allergic Diseases

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

The Changing Field of Melanoma: Ipilimumab.

Evaluating BTK Inhibitors in CLL

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Preparing for Checkpoint Inhibitors in Breast Cancer

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

Checkpoint Inhibitors in First-Line Advanced NSCLC

Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.

Moving Care Forward in Advanced Gastric Cancer

Current Status of Biomarkers for Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors in Lung Cancer

The Nurse View.

Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice

The Nurse View: Practice Pearls in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Overview of irAEs. Management of Immune-Related Adverse Events for Patients Receiving Checkpoint Inhibitor Therapy.

Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Program Overview

Immune Checkpoint Inhibitors

CTLA-4 and PD-1 Pathway Blockade

Immune Checkpoint Inhibitors (cont)

Approved Indications for ICP Inhibitors as of December 2018

Approved Indications for ICP Inhibitors as of December 2018 (cont)

Approved Indications for ICP Inhibitors as of December 2018 (cont)

Checkpoint Inhibitor Toxicities

Management of irAEs in Patients Treated With ICP Inhibitors

Management of irAEs in Patients Treated With ICP Inhibitors (cont)

Rash/Inflammatory Dermatitis

Colitis (Highlights)

Hypothyroidism (Highlights)

Pneumonitis

Immunotherapy irAE Summary

Patient Case

Counseling Patients

Counseling the Healthcare Team

Case (cont)

Discussion

Key Pharmacy Interventions and Counseling

Follow-Up

Important Prescribing Considerations

Important Prescribing Considerations (cont)

Important Prescribing Considerations (cont)

Conclusions

Abbreviations

Abbreviations (cont)